| Quarterly Financials | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 681 | 916 | 852 | 895 | 935 | 1,216 | 1,132 | 1,109 | 1,168 | 931 | 1,110 | 1,000 | 824 | 1,246 | 1,427 | 1,583 | 1,580 | 1,453 | 1,466 | 1,443 | 1,469 |
| Expenses | 395 | 472 | 534 | 595 | 560 | 718 | 704 | 714 | 755 | 587 | 748 | 649 | 673 | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 |
| EBITDA | 286 | 445 | 318 | 299 | 375 | 498 | 428 | 395 | 414 | 344 | 363 | 351 | 151 | 332 | 377 | 394 | 401 | 316 | 357 | 418 | 392 |
| Operating Profit % | 38 % | 47 % | 36 % | 31 % | 37 % | 38 % | 35 % | 33 % | 32 % | 32 % | 28 % | 31 % | 14 % | 24 % | 24 % | 23 % | 23 % | 19 % | 21 % | 26 % | 24 % |
| Depreciation | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 28 | 31 | 35 | 37 | 38 | 38 | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 2 | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 |
| Profit Before Tax | 262 | 420 | 293 | 273 | 349 | 472 | 401 | 366 | 381 | 309 | 324 | 311 | 111 | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 |
| Tax | 67 | 106 | 74 | 69 | 89 | 121 | 99 | 93 | 95 | 79 | 83 | 79 | 33 | 67 | 96 | 91 | 106 | 75 | 93 | 95 | 102 |
| Net Profit | 195 | 314 | 219 | 204 | 260 | 351 | 302 | 273 | 286 | 229 | 241 | 232 | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 |
| EPS in ₹ | 12.57 | 20.24 | 14.12 | 12.83 | 15.93 | 21.41 | 18.37 | 16.62 | 17.40 | 13.93 | 14.65 | 14.08 | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 |
Gland Pharma
1,588.60
+10.40
(0.66%)
Market Cap
26,001.90 Cr
EPS
46.90
PE Ratio
37.28
Dividend Yield
1.14 %
Industry
Healthcare52 Week High
2,220.95
52 Week Low
1,277.80
PB Ratio
2.85
Debt to Equity
0.02
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from10 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,677.60 | #1 4,07,839.00 | 35.55 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 42.28 | |
6,612.00 | 1,76,045.50 | 80.38 | 8,184.00 | 0.89 | 1,600 | 23.05 | 63.47 | |
1,465.70 | 1,19,276.70 | 22.62 | 26,520.70 | 14.17 | 4,155 | 30.28 | 44.20 | |
3,174.70 | 1,06,986.00 | 55.56 | 10,785.70 | 11.59 | 1,656 | 10.91 | 44.55 | |
1,251.20 | 1,04,156.70 | #1 18.42 | 28,905.40 | 12.36 | 5,578 | 21.14 | 67.52 | |
2,467.70 | 1,01,568.60 | 51.21 | 10,615.60 | 19.57 | 1,942 | -10.91 | 48.86 | |
930.00 | 93,051.50 | 19.92 | 19,831.50 | 13.82 | 3,831 | -0.19 | 63.14 | |
1,957.70 | 89,943.10 | 27.40 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 43.05 | |
1,147.80 | 68,122.20 | 19.71 | 29,559.20 | 17.55 | 3,169 | -0.50 | 43.00 | |
30,455.00 | 64,491.60 | 45.58 | 6,097.20 | 10.80 | 1,201 | 27.83 | 50.48 |
Forecast
Actual
Growth Rate
Revenue Growth
50.97 %
Net Income Growth
-1.09 %
Cash Flow Change
173.87 %
ROE
-9.79 %
ROCE
-5.23 %
EBITDA Margin (Avg.)
-21.30 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 |
| Fixed Assets | 968 | 954 | 1,502 | 1,571 | 3,947 |
| Current Assets | 2,846 | 5,124 | 5,852 | 6,901 | 5,645 |
| Capital Work in Progress | 189 | 338 | 191 | 177 | 238 |
| Investments | 0 | 0 | 155 | 0 | 0 |
| Other Assets | 2,930 | 5,204 | 5,986 | 7,030 | 6,477 |
| Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 |
| Current Liabilities | 359 | 513 | 582 | 729 | 1,398 |
| Non Current Liabilities | 81 | 80 | 94 | 90 | 539 |
| Total Equity | 3,646 | 5,903 | 7,158 | 7,959 | 8,724 |
| Reserve & Surplus | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 |
| Share Capital | 16 | 16 | 16 | 17 | 17 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 |
| Investing Activities | -761 | -1,520 | -999 | 1,211 | -1,749 |
| Operating Activities | 701 | 605 | 791 | 364 | 997 |
| Financing Activities | -7 | 1,239 | 35 | 15 | -799 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 58.25 % | 58.14 % | 58.02 % | 58.00 % | 58.00 % | 57.87 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 4.91 % | 0.00 % | 3.59 % | 6.88 % | 4.47 % | 5.04 % | 6.90 % |
| DIIs | 10.69 % | 11.57 % | 11.39 % | 11.21 % | 11.94 % | 16.71 % | 20.58 % | 23.13 % | 23.23 % | 23.38 % | 22.45 % | 23.14 % | 25.23 % | 32.83 % | 35.37 % | 34.80 % | 33.27 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.30 % | 3.72 % | 3.77 % | 3.58 % | 3.69 % | 3.70 % | 3.77 % | 4.02 % | 4.26 % | 5.60 % | 4.52 % | 3.79 % | 3.28 % | 3.33 % | 3.28 % | 3.30 % | 2.99 % |
| Others | 27.76 % | 26.58 % | 26.81 % | 27.21 % | 26.37 % | 21.71 % | 17.78 % | 14.98 % | 14.64 % | 13.16 % | 10.27 % | 15.22 % | 10.04 % | 5.12 % | 5.04 % | 5.04 % | 5.01 % |
| No of Share Holders | 84,467 | 98,203 | 1,09,326 | 1,09,097 | 1,09,098 | 1,17,339 | 1,27,879 | 1,48,469 | 1,50,578 | 1,81,747 | 1,61,627 | 1,36,021 | 1,22,375 | 1,22,665 | 1,22,358 | 1,21,075 | 1,13,788 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Aug 2025 |  Annual General Meeting | NA | 28 Aug 2025 | 1,484.15 | 1,580.75 |
| 20 May 2025 |  Quarterly Result Announcement | NA | 20 May 2025 | 1,418.75 | 1,484.15 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 1,672.75 | 1,530.45 |
| 04 Nov 2024 | Quarterly Result Announcement | NA | 04 Nov 2024 | 1,675.30 | 1,644.85 |
| 30 Aug 2024 | Annual General Meeting | NA | 30 Aug 2024 | 1,800.25 | 1,849.00 |
| 16 Aug 2024 |  Dividend | ₹ 20.00 /share | 16 Aug 2024 | 1,800.25 | 1,958.25 |
Announcements
Compliances-Reg.24(A)-Annual Secretarial Compliance
3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript3 days ago
3 days agoGrant Of Stock Options (Grant I) Under Gland Pharma Employee Stock Option Scheme 2025 (ESOP 2025 Or Scheme)7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Change in Management9 days ago
9 days agoThe 47Th AGM Of The Company Is Scheduled To Be Held On Thursday August 28 202510 days ago
10 days agoBoard Fixes August 14 2025 As The Record Date For Final Dividend10 days ago
10 days agoCorporate Action-Board approves Dividend10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation10 days ago
10 days agoBoard Meeting Outcome for Outcome Of Board Meeting - May 20 202510 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoIntimation Regarding ESOP Compensation Committee MeetingMay 18, 2025
May 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 06, 2025
May 06, 2025Board Meeting Intimation for To Approve The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025 And Recommend The Payment Of Final Dividend For FY 2024-25May 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 30, 2025
Apr 30, 2025Change In Contact Details Of RTAApr 24, 2025
Apr 24, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Apr 16, 2025
Apr 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 03, 2025
Apr 03, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 31, 2025
Mar 31, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 31, 2025
Mar 31, 2025Closure of Trading WindowMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 24, 2025
Mar 24, 2025ESOP Scheme 2025Mar 22, 2025
Mar 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Mar 11, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 11, 2025
Mar 11, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 11, 2025
Mar 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 01, 2025
Mar 01, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 28, 2025
Feb 28, 2025Approval Of Gland Pharma Employee Stock Option Scheme 2025 By Board Of DirectorsFeb 26, 2025
Feb 26, 2025Board Meeting Outcome for Outcome Of Board Meeting - 26Th February 2025Feb 26, 2025
Feb 26, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 26, 2025
Feb 26, 2025Conclusion Of US FDA Inspection At CompanyS JNPC Facility VisakhapatnamFeb 25, 2025
Feb 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Feb 24, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Feb 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Feb 07, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 03, 2025
Feb 03, 2025Integrated Filing (Financial)Feb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2025
Feb 03, 2025Board Meeting Outcome for Outcome Of Board Meeting For The Quarter Ended December 31 2024Feb 03, 2025
Feb 03, 2025Unaudited Financial Results For The Quarter Ended December 31 2024Feb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 30, 2025
Jan 30, 2025Technical Indicators
RSI(14)
Neutral 68.02
ATR(14)
Less Volatile 48.74
STOCH(9,6)
Neutral 64.45
STOCH RSI(14)
Neutral 77.37
MACD(12,26)
Bullish 12.40
ADX(14)
Weak Trend 20.48
UO(9)
Bearish 42.34
ROC(12)
Uptrend But Slowing Down 8.01
WillR(14)
Overbought -18.43
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 Sundaram Focused Fund Direct-Growth | 0 | 0.00% | -3.67% | -3.71% | Apr 2025 | |
 SBI Equity Savings Fund Direct-Growth | 0 | 0.00% | -0.55% | -0.55% | Apr 2025 | |
 DSP Business Cycle Fund Direct - Growth | 56448 | 0.77% | -0.44% | -0.55% | Apr 2025 | |
 Mirae Asset ELSS Tax Saver Fund Direct-Growth | 1861382 | 1.05% | -0.43% | -0.58% | Apr 2025 | |
 ICICI Prudential MNC Fund Direct - Growth | 338737 | 2.95% | -0.43% | -0.47% | Apr 2025 | |
| DSP Healthcare Fund Direct - Growth | 920673 | 4.43% | -0.43% | -0.41% | Apr 2025 | |
| Mirae Asset Healthcare Fund Direct - Growth | 474076 | 2.47% | -0.43% | -0.95% | Apr 2025 | |
 Nippon India Pharma Fund Direct-Growth | 1529352 | 2.59% | -0.42% | -0.52% | Apr 2025 | |
| ICICI Prudential Large & Mid Cap Fund Direct Plan-Growth | 952390 | 0.66% | 0.40% | 0.41% | Apr 2025 | |
 Navi Nifty Midcap 150 Index Fund Direct - Growth | 0 | 0.00% | -0.40% | -0.43% | Apr 2025 | |
| DSP Multicap Fund Direct - Growth | 274606 | 1.86% | -0.37% | -0.52% | Apr 2025 | |
| Mirae Asset Focused Fund Direct - Growth | 1146776 | 2.10% | -0.37% | -0.41% | Apr 2025 | |
 UTI MNC Fund Direct-Growth | 424791 | 2.21% | -0.35% | -0.40% | Apr 2025 | |
 HDFC Pharma And Healthcare Fund Direct - Growth | 259002 | 2.18% | -0.34% | -0.72% | Apr 2025 | |
| Mirae Asset Midcap Fund Direct - Growth | 1515740 | 1.38% | -0.34% | -1.00% | Apr 2025 | |
| SBI Healthcare Opportunities Fund Direct Plan-Growth | 540000 | 2.06% | -0.34% | -0.49% | Apr 2025 | |
| UTI Healthcare Fund Direct-Growth | 180000 | 2.43% | -0.32% | -1.10% | Apr 2025 | |
| HDFC Manufacturing Fund Direct - Growth | 1652000 | 1.97% | -0.30% | -0.41% | Apr 2025 | |
| Mirae Asset Large & Midcap Fund Direct-Growth | 2923448 | 1.08% | -0.29% | -0.62% | Apr 2025 | |
 Aditya Birla Sun Life MNC Fund Direct-Growth | 461607 | 1.89% | -0.29% | -0.34% | Apr 2025 | |
| ICICI Prudential India Opportunities Fund Direct - Growth | 2684881 | 1.38% | -0.28% | -0.37% | Apr 2025 | |
 Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth | 3509 | 2.03% | -0.27% | -0.48% | Apr 2025 | |
 Tata Nifty MidSmall Healthcare Index Fund Direct - Growth | 19509 | 2.03% | -0.27% | -0.49% | Apr 2025 | |
| ICICI Prudential Midcap Direct Plan-Growth | 691034 | 1.63% | -0.27% | -0.36% | Apr 2025 | |
| Mirae Asset Multicap Fund Direct - Growth | 334229 | 1.34% | -0.25% | -0.35% | Apr 2025 |
About Gland Pharma
Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs. The company has 284 ANDA filings in the US, with 234 approved. It expanded its business to include contract development, dossier preparation, and technology transfer. In 2023, Gland Pharma acquired Cenexi through its Singapore subsidiary, adding 7 new subsidiaries. The company offers various delivery systems and key molecules such as Heparin Sodium and Enoxaparin Sodium Injections.
Listing Date
20 Nov, 2020(4 Years,
40 days)
Website
Chairperson NameYiu Kwan Stanley Lau
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
